incidence of gvhd in myeloma treated with daratumumab after allo-hct
Published 3 years ago • 59 plays • Length 2:01Download video MP4
Download video MP3
Similar videos
-
1:18
the epidemiology and treatment of chronic gvhd post-allosct
-
4:59
incidence, prevention, and management of infections in multiple myeloma
-
0:52
advances in treatment modalities to reduce the risk of gvhd in allografted patients
-
2:37
incidence of second primary malignancies in lymphoma survivors
-
5:07
daratumumab in the management of al amyloidosis
-
4:06
incidence of germline mutations in patients with myeloid neoplasms with antecedent solid tumors
-
3:15
comparing ttnt or death between front-line drd and vrd in transplant-ineligible multiple myeloma
-
13:18
full throttle: one-on-one with dr. rashmi kanagal-shamanna
-
5:03
how 3d printing is the key to nanotechnology
-
16:41
the relationship between the gut microbiome and gvhd
-
1:38
the genomic definition of high-risk myeloma
-
2:14
the influence of graft source and composition on gvhd
-
1:53
the future of multiple myeloma treatment
-
1:33
sequencing and the management of adverse events when administering bispecifics for myeloma
-
1:03
tackling the unmet needs in gvhd from prophylaxis to treatment
-
4:34
modulation of the microbiota for the treatment of gvhd
-
1:24
gem2014main: assessing mrd with ngf in bone marrow and ms in peripheral blood in multiple myeloma
-
1:31
five-year follow-up of olutasidenib for idh1-mutated r/r aml
-
1:37
mrd in myeloma
-
1:30
the prognostic value of patient-reported outcomes in mds
-
1:37
a prospective trial of radiation-free chemotherapy in high- and low-risk hl
-
4:45
a first-in-human trial of linvoseltamab (regn5458) in r/r myeloma: updated phase i data